Zalicus Inc Com (NASDAQ:ZLCS)
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
Sn8keiis
(< 20)
Submitted: 1/2/2013 8:29:03 AM :
Start Price:
$0.66
ZLCS Score:
-27.78
Bargain price for a stock with HUGE potential. 1000 shares for less than a $1000 mitigates risk.
Recs
bSITE612
(87.85)
Submitted: 10/15/2012 4:33:35 PM :
Start Price:
$0.60
ZLCS Score:
-19.56
Despite recent disappointment in Synavive, the company still holds two products (Z160 & Z944) which have value if successful.
Recs
velo15
(< 20)
Submitted: 9/29/2012 5:21:09 PM :
Start Price:
$0.75
ZLCS Score:
-38.42
Remnants of dysfunctional past mngmnt gone now...
Recs
zzlangerhans
(99.76)
Submitted: 9/26/2012 12:20:55 AM :
Start Price:
$0.79
ZLCS Score:
-40.74
I'm not going to waste a lot of time on Zalicus. This is one of the most heavily and ridiculously pumped stocks in microcap biopharma and no matter how many times the company fails the expectations that have been manufactured, the pumpers are able to resuscitate it. Now, with the cap back down below 89M in the wake of Synavive failure, is as good a time as any to plant a green flag here. If the stock keeps drifting downward before the inevitable pumping and manipulation around the company's ion channel blockers begins then I might actually go along for the ride with real money next time.
Recs
Momentum21
(97.99)
Submitted: 9/19/2012 1:03:37 PM :
Start Price:
$1.38
ZLCS Score:
-75.76
bought some in RL at .88...these guys have time and space. speculators out...investors in!
Recs
tenmiles
(99.92)
Submitted: 9/10/2012 10:06:30 AM :
Start Price:
$0.93
ZLCS Score:
-52.78
Back in after 30% selling
Recs
acumulator
(< 20)
Submitted: 8/20/2012 7:46:10 PM :
Start Price:
$1.26
ZLCS Score:
-70.22
The potential for good news on there pain drug Synavive, could move the price of this stock up in the next several months which could make this a good trade.
Recs
slycat910
(59.04)
Submitted: 8/16/2012 5:37:35 PM :
Start Price:
$1.38
ZLCS Score:
-74.33
Nobody likes pain.
Recs
Fishboy1970
(< 20)
Submitted: 6/23/2012 9:27:42 AM :
Start Price:
$1.27
ZLCS Score:
-79.92
Just a hunch!
Recs
stevebkca09
(< 20)
Submitted: 5/30/2012 6:26:14 PM :
Start Price:
$0.99
ZLCS Score:
-67.52
Phase II trials will spark interest. Novartis partnership will likewise generate positive publicity and demand.
Recs
SamsaricSufferer
(< 20)
Submitted: 4/4/2012 4:37:48 PM :
Start Price:
$1.15
ZLCS Score:
-68.56
Hard to miss at this price. Typical speculative biotech with typical speculative biotech issues. However.....ZLCS is priced post negative binary event, post dilutional stock issuance. Or to flip it around enough cash to fund operations for the near term (about 50M). Broad pipeline in clinical trial progression. Expanding revenue on Exalgo going forward to blunt burn rate.
Recs
RBuskey106
(33.54)
Submitted: 4/4/2012 12:56:55 PM :
Start Price:
$1.14
ZLCS Score:
-67.93
Chart Play
Recs
TMFCop
(85.93)
Submitted: 4/1/2012 8:46:05 AM :
Start Price:
$1.20
ZLCS Score:
-69.54
The market is discounting the potential a new 32 mg dose of Exalgo, focusing instead on the generics agreement affecting lower dosage amounts. With the 32 mg dosage key to achieving peak sales of $200 million and ZLCS having exclusivity thru July 2014, the stock is trading at a discount.
If ZLCS also hits with some of its treatments currently in clinical trials, there could be a huge lift in its stock price.
Recs
k2merlinsix
(71.61)
Submitted: 1/23/2012 9:48:04 AM :
Start Price:
$1.13
ZLCS Score:
-74.23
ZLCS is growing their pipeline. The start of two Phase I ion drugs in addition to Synavive in Phase 2b and Prednisporin entering into Phase III studies for conjunctivits and lastly Novartis filling 3 patents and a pending 4th application that explicitly call out the use of ZLCSs cHTS technology shows plenty of momentum int his little stock and a very bright future as these drugs and partnerships mature.
Recs
DillonD
(< 20)
Submitted: 12/2/2011 11:12:46 AM :
Start Price:
$0.96
ZLCS Score:
-71.70
Have potential to gain up to %400 in the short-term
Recs
thatkidfromseat
(< 20)
Submitted: 11/2/2011 3:36:00 PM :
Start Price:
$1.29
ZLCS Score:
-88.39
Zalicus has an extreme amount of room for growth and has shown that they can successfully make a medical product in a somewhat limited market. If they stay the course, they could be a huge pick for those that take the risk
Recs
simischuster
(< 20)
Submitted: 10/29/2011 12:48:52 PM :
Start Price:
$1.28
ZLCS Score:
-84.78
10% owner (MPM) has completed their planned sell of 3.5M shares from Sept '11. Stock has 10 analysts and avg 4.2 pps estimate. Zack's analyst PN has a you tube video that explains the story. Very well positioned for pain prevention market. Great pipeline and great partnerships.
Recs
kdb1952
(< 20)
Submitted: 10/28/2011 10:18:06 PM :
Start Price:
$1.28
ZLCS Score:
-84.78
i suffer from osteo arthritis and know many people who also suffer. the mere prospect of significant relief blows me away. if synavive is 1/2 what they are saying, it's pure gold! gotta go with z
Recs
Lcrazylegs84
(24.74)
Submitted: 10/1/2011 1:04:35 AM :
Start Price:
$0.98
ZLCS Score:
-88.15
going up
Recs
yurik515
(< 20)
Submitted: 7/7/2011 2:31:41 AM :
Start Price:
$2.69
ZLCS Score:
-100.11
Solid cash on hand, short term investment and cash equivalents, expanding drug pipeline, secured financing for future R&D programs, partnership with Sanofi and Novartis - all of these factors contribute to its (Zalicus) great long term story.
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 46 : 1 2 3 Next »